No black box warning on record for Kygevvi

As of the latest FDA labeling reviewed, Kygevvi (DOXECITINE AND DOXRIBTIMINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Kygevvi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Elevated Liver Transaminase Levels : Obtain baseline liver transaminase (ALT, AST) and total bilirubin levels prior to treatment initiation with KYGEVVI. If signs or symptoms consistent with liver injury are observed, interrupt treatment. Consider permanently discontinuing KYGEVVI if signs/symptoms consistent with liver injury persist or worsen. Monitor patients yearly a

No black box warning on record for Kygevvi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Elevated Liver Transaminase Levels : Obtain baseline liver transaminase (ALT, AST) and total bilirubin levels prior to treatment initiation with KYGEVVI. If signs or symptoms consistent with liver injury are observed, interrupt treatment. Consider permanently discontinuing KYGEVVI if signs/symptoms consistent with liver injury persist or worsen. Monitor patients yearly a

Kygevvi Black Box Warning

No black box warning on record for Kygevvi

Other warnings & precautions

Kygevvi Black Box Warning

No black box warning on record for Kygevvi

Other warnings & precautions